TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Brief Summary: This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.


Options:
A: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo for Bococizumab (PF-04950615;RN316), Other: Placebo for atorvastatin | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: OTHER; Name: Placebo for Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Placebo for atorvastatin; Assigned to Arm(s): Placebo
B: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gene and Environment in Schizophrenia- Research Groups in Madrid
Brief Summary: The AGES-CM consortium aims to study the interaction between the polymorphisms of the candidate genes related with neurodevelopment, neurotransmission, brain progressive changes, cognitive functioning and stressful life events (prospective- and retrospectively assessed) and the association of the interactions with structural and functional brain measures, neuropsychological performance, biochemical and oxidative status in both in patients and controls. The investigators study aimed to examine the effectiveness of a parallel, structured, and specific psychoeducational group intervention (PE) for adolescent patients and their families by comparing it with treatment as usual).


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Counselling (SC); Assigned to Arm(s): N/A
B: Arm Label: Family Focused Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Family Focused Treatment | Arm Label: Enhanced Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Care | Intervention Type: BEHAVIORAL; Name: Family Focused Treatment; Assigned to Arm(s): Family Focused Treatment | Intervention Type: BEHAVIORAL; Name: Enhanced Care; Assigned to Arm(s): Enhanced Care
C: Arm Label: Cognitive Remediation Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Remediation Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Remediation Therapy; Assigned to Arm(s): Cognitive Remediation Therapy
D: Arm Label: treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: treatment as usual | Arm Label: Psychoeducation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation group treatment | Intervention Type: BEHAVIORAL; Name: treatment as usual; Assigned to Arm(s): treatment as usual | Intervention Type: BEHAVIORAL; Name: Psychoeducation group treatment; Assigned to Arm(s): Psychoeducation Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Center, Placebo Controlled Clinical Study in Desensitization vs Tolerance Induction in Peanut Allergy Subjects
Brief Summary: Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period

Secondary Objectives:

* Identify the basic immune mechanisms which can explain the differences in the effects of OIT in desensitized vs. tolerant individuals.
* Determine whether immune monitoring measurements reflecting underlying mechanisms during OIT can be used to predict responses to OIT in individual subjects and, ultimately, to improve the safety and efficacy outcomes in peanut OIT protocols.


Options:
A: Arm Label: Oat Flour 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oat Flour | Arm Label: Peanut Protein 4,000mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peanut Protein 4,000mg, Drug: Oat Flour | Arm Label: Peanut Protein 300 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oat Flour, Drug: Peanut Protein 300 mg | Intervention Type: DRUG; Name: Peanut Protein 4,000mg; Assigned to Arm(s): Peanut Protein 4,000mg | Intervention Type: DRUG; Name: Oat Flour; Assigned to Arm(s): Oat Flour 600 mg, Peanut Protein 300 mg, Peanut Protein 4,000mg | Intervention Type: DRUG; Name: Peanut Protein 300 mg; Assigned to Arm(s): Peanut Protein 300 mg
B: Arm Label: Part A: Dupilumab or Placebo; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Part B: Dupilumab or Placebo; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Part C: Dupilumab; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Part A: Dupilumab or Placebo, Part B: Dupilumab or Placebo, Part C: Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A: Dupilumab or Placebo, Part B: Dupilumab or Placebo
C: Arm Label: Drug; Type: EXPERIMENTAL; Interventions: Drug: Montelukast/ Singulair | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Montelukast/ Singulair; Assigned to Arm(s): Drug | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide 1mg orodispersible tablet twice daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo orodispersible tablet twice daily | Intervention Type: DRUG; Name: Budesonide 1mg orodispersible tablet twice daily; Assigned to Arm(s): Budesonide | Intervention Type: DRUG; Name: Placebo orodispersible tablet twice daily; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight (VLBW) Preterm Neonates: A Multi-center Randomized Clinical Trial
Brief Summary: The goal of this protocol is to establish a randomized clinical trial comparing the use of cord blood vs. infant blood with the primary outcome of comparing both the absolute hemoglobin concentration and the percent change in hemoglobin concentration from baseline around 24 hours of life.


Options:
A: Arm Label: Infant Blood; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Drawing admission labs from infant blood | Arm Label: Cord Blood; Type: EXPERIMENTAL; Interventions: Procedure: Drawing admission labs from cord blood | Intervention Type: PROCEDURE; Name: Drawing admission labs from cord blood; Assigned to Arm(s): Cord Blood | Intervention Type: PROCEDURE; Name: Drawing admission labs from infant blood; Assigned to Arm(s): Infant Blood
B: Arm Label: Darbepoetin; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin; Assigned to Arm(s): Darbepoetin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: "liberal" transfusion triggers; Type: EXPERIMENTAL; Interventions: Other: red blood cell transfusion | Arm Label: "restrictive" transfusion triggers; Type: ACTIVE_COMPARATOR; Interventions: Other: red blood cell transfusion | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "liberal" transfusion triggers | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "restrictive" transfusion triggers
D: Arm Label: Low Threshold Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Restricted red cell transfusion | Arm Label: High Threshold Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Liberal Cell Transfusion | Intervention Type: PROCEDURE; Name: Liberal Cell Transfusion; Assigned to Arm(s): High Threshold Transfusion | Intervention Type: PROCEDURE; Name: Restricted red cell transfusion; Assigned to Arm(s): Low Threshold Transfusion

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Training Program in Patients Hospitalized for Community-acquired Pneumonia
Brief Summary: Hospitalized patients with community-acquired pneumonia (CAP) have reduced functional capacity, peripheral muscle strength and quality of life. Despite the high incidence and severity has not yet been demonstrated whether a physical training program can change these outcomes. Objectives: To evaluate the effects of an exercise training program in patients hospitalized for CAP, to compare this effects with traditional physical therapy and assess whether the inflammatory markers correlate with the functional status of the patient and type of treatment. Methods: A controlled, prospective, randomized clinical trial. Patients hospitalized for CAP, adults, conscious, hemodynamically stable and independent to walk will be studied. In the first day, a medical history, measured dyspnea, incremental shuttle walk test, Glittre test, measurement of peripheral muscle strength, spirometry, and the application of quality of life questionnaire Shor Form 36 will be held. The measurement of inflammatory markers (C-reactive protein and tumor necrosis factor) will also be held. Patients will be randomized into two groups: one will perform a program of physical training (stretching, active resistance exercises and aerobic exercises) and the other group held the traditional physical therapy (bronchial hygiene, breathing exercises and walking) for eight days. On the tenth day the same assessment will be carried out initially described.


Options:
A: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Experimental group | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Experimental group; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy program | Arm Label: Control group; Type: OTHER; Interventions: Drug: cephalosporin with or without erythromycin | Intervention Type: DRUG; Name: cephalosporin with or without erythromycin; Assigned to Arm(s): Control group | Intervention Type: OTHER; Name: Physiotherapy program; Assigned to Arm(s): Experimental group
C: Intervention Type: OTHER; Name: other; Assigned to Arm(s): N/A
D: Arm Label: Physiotherapy+conventional treatment; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy+conventional treatment | Arm Label: Conventional treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional treatment | Intervention Type: OTHER; Name: Physiotherapy+conventional treatment; Assigned to Arm(s): Physiotherapy+conventional treatment | Intervention Type: DRUG; Name: Conventional treatment; Assigned to Arm(s): Conventional treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension
Brief Summary: This study (ARD-3150-1202, ORBIT-4) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic fibrosis (non-CF) bronchiectasis with a history of pulmonary exacerbations and chronic P. aeruginosa infections.


Options:
A: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 28 Days on/off (Placebo 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14)
B: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
C: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
D: Arm Label: Ciprofloxacin dispersion for inhalation; Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin dispersion for inhalation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin dispersion for inhalation; Assigned to Arm(s): Ciprofloxacin dispersion for inhalation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This research represents a randomized trial of a program to improve timely postnatal care, comparing post-natal check-ups performed by community health workers delivered either by phone or in person to a control group. The study hypothesis is that when community health workers check on women three days after their delivery we will see improvements in the detection of maternal and child complications, better knowledge of complications and an increase in behaviors that are expected to lead to improved maternal and child health.


Options:
A: Arm Label: Postpartum Visit 3-4 Weeks; Type: EXPERIMENTAL; Interventions: Behavioral: Postpartum Visit 3-4 Weeks | Arm Label: Postpartum Visit 6-8 Weeks; Type: EXPERIMENTAL; Interventions: Behavioral: Postpartum Visit 6-8 Weeks | Intervention Type: BEHAVIORAL; Name: Postpartum Visit 3-4 Weeks; Assigned to Arm(s): Postpartum Visit 3-4 Weeks | Intervention Type: BEHAVIORAL; Name: Postpartum Visit 6-8 Weeks; Assigned to Arm(s): Postpartum Visit 6-8 Weeks
B: Arm Label: Durham Connects Eligible Group; Type: EXPERIMENTAL; Interventions: Other: Durham Connects | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Durham Connects; Assigned to Arm(s): Durham Connects Eligible Group
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
D: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This research represents a randomized trial of a program to improve timely postnatal care, comparing post-natal check-ups performed by community health workers delivered either by phone or in person to a control group. The study hypothesis is that when community health workers check on women three days after their delivery we will see improvements in the detection of maternal and child complications, better knowledge of complications and an increase in behaviors that are expected to lead to improved maternal and child health.


Options:
A: Arm Label: Individual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: CenteringPregnancy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CenteringPregnancy | Arm Label: CenteringPregnancyPlus; Type: EXPERIMENTAL; Interventions: Behavioral: CenteringPregnancy, Behavioral: CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancy; Assigned to Arm(s): CenteringPregnancy, CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: CenteringPregnancyPlus; Assigned to Arm(s): CenteringPregnancyPlus | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Individual Care
B: Arm Label: Neonatal Kit; Type: EXPERIMENTAL; Interventions: Device: Neonatal Kit | Arm Label: Neonatal Stimulation; Type: EXPERIMENTAL; Interventions: Behavioral: Neonatal Stimulation | Arm Label: Neonatal Kit and Neonatal Stimulation; Type: EXPERIMENTAL; Interventions: Device: Neonatal Kit, Behavioral: Neonatal Stimulation | Arm Label: Control (Standard Care); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Neonatal Kit; Assigned to Arm(s): Neonatal Kit, Neonatal Kit and Neonatal Stimulation | Intervention Type: BEHAVIORAL; Name: Neonatal Stimulation; Assigned to Arm(s): Neonatal Kit and Neonatal Stimulation, Neonatal Stimulation
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Workers; Type: EXPERIMENTAL; Interventions: Behavioral: community health workers | Intervention Type: BEHAVIORAL; Name: community health workers; Assigned to Arm(s): Community Health Workers
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This research represents a randomized trial of a program to improve timely postnatal care, comparing post-natal check-ups performed by community health workers delivered either by phone or in person to a control group. The study hypothesis is that when community health workers check on women three days after their delivery we will see improvements in the detection of maternal and child complications, better knowledge of complications and an increase in behaviors that are expected to lead to improved maternal and child health.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
B: Arm Label: Smartphone-enabled app for linkage to care; Type: EXPERIMENTAL; Interventions: Other: Smartphone application, Device: Smartphone | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smartphone application; Assigned to Arm(s): Smartphone-enabled app for linkage to care | Intervention Type: DEVICE; Name: Smartphone; Assigned to Arm(s): Smartphone-enabled app for linkage to care
C: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of care | Arm Label: Text Messaging; Type: EXPERIMENTAL; Interventions: Behavioral: Text Messaging | Intervention Type: BEHAVIORAL; Name: Standard of care; Assigned to Arm(s): Standard of care | Intervention Type: BEHAVIORAL; Name: Text Messaging; Assigned to Arm(s): Text Messaging
D: Arm Label: Text message vaccine reminders; Type: EXPERIMENTAL; Interventions: Other: Text Message, Other: automated call | Arm Label: automated phone call from clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: automated call | Intervention Type: OTHER; Name: Text Message; Assigned to Arm(s): Text message vaccine reminders | Intervention Type: OTHER; Name: automated call; Assigned to Arm(s): Text message vaccine reminders, automated phone call from clinic

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)
Brief Summary: The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.


Options:
A: Intervention Type: DRUG; Name: Omega-3-acid ethyl ester 90 (n-3 PUFA); Assigned to Arm(s): N/A
B: Arm Label: EPANOVA; Type: EXPERIMENTAL; Interventions: Drug: Epanova® (omega-3 carboxylic acids) | Arm Label: Corn oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: corn oil control | Intervention Type: DRUG; Name: Epanova® (omega-3 carboxylic acids); Assigned to Arm(s): EPANOVA | Intervention Type: DRUG; Name: corn oil control; Assigned to Arm(s): Corn oil
C: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A

Answer: B